1. Scrip
  2. >>Business

Amgen’s Growth Story Relies Mainly On Continuing Plot Lines

Forecasts Mid-Single-Digit Revenue CAGR Through 2030

 
• By Mandy Jackson

Established brands Repatha and Otezla, new launches Lumakras and Tezspire, and the Amjevita-led biosimilars portfolio will provide most of the company’s growth through the end of this decade.

Top view of vintage typewriter with books and copy space
Amgen is writing a growth story built on Repatha, Otezla, biosimilars and new launches • Source: Alamy

Amgen, Inc. executives told investors the story of how it grew to a biopharmaceutical company with 25 commercial brands across 100 global markets during an 8 February business review, and laid out how it plans to write the next chapters of its growth.

Including 2022, in which it expects revenue to total $25.4bn to $26

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

AbbVie On MFN: ‘We Have To Take It Seriously’

 
• By Jessica Merrill

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.

Industry Leaders Grapple With Trump’s MFN Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 
• By Andrew McConaghie

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.